纤维蛋白原与白蛋白比值在非小细胞肺癌中的预后及临床病理价值：一项荟萃分析

Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in non-small cell lung cancer: a meta-analysis.

作者信息

Tong Ling, Hu Hui, Li Jiashan, Pan Lihai

机构信息

Operating Room, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.

Department of Cardiology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.

出版信息

World J Surg Oncol. 2025 May 16;23(1):196. doi: 10.1186/s12957-025-03832-z.

DOI:10.1186/s12957-025-03832-z

PMID:40380342

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12082923/

Abstract

BACKGROUND

The fibrinogen-to-albumin ratio (FAR) has been explored for its role in predicting non-small cell lung cancer (NSCLC) prognosis, but findings remain inconsistent. This study aimed to determine the exact impact of FAR on predicting NSCLC prognosis through a meta-analysis.

METHODS

This study conducted a comprehensive search of PubMed, Web of Science, Embase, Cochrane Library, and CNKI up to April 2, 2025, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the prognostic value of FAR in NSCLC.

RESULTS

This meta-analysis included seven studies with a total of 2,655 cases. The pooled analysis revealed that an elevated FAR significantly predicted poor overall survival (OS) (HR = 1.82, 95% CI = 1.56-2.14, p < 0.001) and poor progression-free survival (PFS) (HR = 1.50, 95% CI = 1.29-1.74, p < 0.001) in patients with NSCLC, which was strongly associated with male sex (OR = 1.53, 95% CI = 1.12-2.08, p = 0.008) and tumor size ≥ 5 cm (OR = 1.52, 95% CI = 1.08-2.14, p = 0.017). However, FAR showed no significant correlation with smoking history (OR = 1.44, 95% CI = 0.80-2.59, p = 0.218) or Eastern Cooperative Oncology Group performance status (OR = 1.60, 95% CI = 0.74-3.45, p = 0.230).

CONCLUSION

This meta-analysis suggests that elevated FAR is a strong predictor of OS and PFS in patients with Chinese NSCLC and correlates with larger tumor size.

摘要

背景

纤维蛋白原与白蛋白比值（FAR）在预测非小细胞肺癌（NSCLC）预后中的作用已得到研究，但结果仍不一致。本研究旨在通过荟萃分析确定FAR对预测NSCLC预后的确切影响。

方法

本研究全面检索了截至2025年4月2日的PubMed、Web of Science、Embase、Cochrane图书馆和中国知网，并确定合并风险比（HR）和95%置信区间（CI），以评估FAR在NSCLC中的预后价值。

结果

该荟萃分析纳入了7项研究，共2655例病例。汇总分析显示，FAR升高显著预测NSCLC患者的总生存期（OS）较差（HR = 1.82，95% CI = 1.56 - 2.14，p < 0.001）和无进展生存期（PFS）较差（HR = 1.50，95% CI = 1.29 - 1.74，p < 0.001），这与男性（OR = 1.53，95% CI = 1.12 - 2.08，p = 0.008）和肿瘤大小≥5 cm（OR = 1.52，95% CI = 1.08 - 2.14，p = 0.017）密切相关。然而，FAR与吸烟史（OR = 1.44，95% CI = 0.80 - 2.59，p = 0.218）或东部肿瘤协作组体能状态（OR = 1.60，95% CI = 0.74 - 3.45，p = 0.230）无显著相关性。